Data Loading...

BAD SPRING 2022 final v2 Flipbook PDF

BAD SPRING 2022 final


160 Views
121 Downloads
FLIP PDF NAN

DOWNLOAD FLIP

REPORT DMCA

newsletter

THE BRITISH ASSOCIATION OF DERMATOLOGISTS

GLASGOW British Association of Dermatologists

102nd Annual Meeting 5th–7th July, 2022

VOLUME 25 NUMBER 1

News from patient groups Psychodermatology Network MDT meetings 75th Dowling Club Anniversary

SPRING 2022

The BAD Annual Meeting returns to in-person format this July

Demonstrated sustained relief in Psoriasis at 5 years and in Psoriatic Arthritis at 2 years*1,2

COMPLETE SKIN CLEARANCE • At Week 16: PASI 100 achieved in more than 1/3 of PsO patients treated with TREMFYA®.†3 • Long term: PASI 100 response rate of over 50% at Week 52 sustained at 5 years in PsO patients treated with TREMFYA®.‡1

RAPID JOINT EFFICACY • At Week 4: ACR20 achieved in 20% of PsA patients treated with TREMFYA®. 2 • Long term: 74% ACR20 response rate seen at 1 year and sustained at 2 years in PsA patients treated with TREMFYA®.¶2,4

PROVEN DURABILITY • Most patients who started on TREMFYA®, stayed on TREMFYA® long-term. 2,5

To access educational videos, clinical papers, patient support and more visit https://www.janssenmedicalcloud.co.uk/ or scan the QR code. *Sustained improvements in psoriasis disease severity (as measured by PASI 90 and PASI 100 scores) and sustained improvements in psoriatic arthritis disease severity (as measured by ACR scores, HAQ-DI scores and resolution of enthesitis and dactylitis).1,2 †PASI 100 analysis not part of the statistical analysis plan. 37.4% of patients treated with TREMFYA® achieved PASI 100 at Week 16 (n=329) vs 0.6% of patients treated with placebo (n=174; p